Autolus Therapeutics, a small British company developing cell therapy treatments, is to join the swelling ranks of listed biotech companies using the new anti-cancer technology with a planned IPO on Nasdaq.
The group said on Tuesday it had filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) under the ticker symbol AUTL.
The number of its American depositary shares to be sold in the IPO and the pricing terms have not yet been determined.
Autolus is developing chimeric antigen receptor T-cell (CAR-T) treatments to fight blood cancers and, hopefully, also solid tumors.
The first two CAR-T treatments from Novartis and Gilead Sciences won U.S. approval last year for rare blood cancer and a number of start-up companies, as well as large drugmakers, are investing heavily in the space.
Autolus, which was spun out from University College London in 2014 and uses cell technology pioneered by Dr. Martin Pule, is aiming to develop next-generation CAR-T treatments that it hopes will have an edge over the first wave of therapies.
Its backers include Syncona, Woodford Investment Management and Arix Bioscience.
PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.